The tegsedi market research report is one of a series of new reports that provides tegsedi market statistics, including tegsedi industry global market size, regional shares, competitors with a tegsedi market share, detailed tegsedi market segments, market trends and opportunities, and any further data you may need to thrive in the tegsedi industry. This tegsedi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to growing demand for oral medications, increasing prevalence of comorbid conditions, rising awareness of rare genetic disorders, rising investment in precision medicine, and increasing number of clinical trials. Major trends in the forecast period include technological advancements, personalized medicine, genetic therapies, telemedicine, and combination therapies.
The growing adoption of personalized medicine is expected to significantly boost the growth of the tegsedi market in the future. Personalized medicine involves tailoring medical treatments based on an individual’s genetic profile, lifestyle, and environmental factors, resulting in more effective outcomes. The increased adoption of this approach is driven by advancements in genomic research, improved diagnostic tools, and a rising demand for more targeted therapies. Personalized medicine enhances the efficacy and safety of Tegsedi by customizing treatments for individuals with hereditary transthyretin-mediated amyloidosis, which ensures better therapeutic outcomes and minimizes risks. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, a significant increase from the six approved in 2022. As personalized medicine continues to expand, it will drive further growth in the tegsedi market.
A significant trend in the tegsedi market is the increasing adoption of innovative drug category pricing strategies. These strategies aim to improve accessibility, enhance patient adherence, and facilitate market penetration by balancing cost-effectiveness with therapeutic value. Drug category pricing involves setting prices for medications based on factors such as therapeutic category, efficacy, market demand, and competition within a specific drug class. In October 2021, PTC Therapeutics, a US-based biopharmaceutical company, announced that Tegsedi (inotersen) had received Category 1 classification from Brazil's Câmara de Regulação do Mercado de Medicamentos (CMED). This classification recognizes it as an innovative treatment that offers greater efficacy than existing therapies. Additionally, the Brazilian Health Regulatory Agency (Anvisa) approved it for treating Stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR). Tegsedi became the first antisense medication in Brazil to target the root cause of the disease, and clinical studies have shown that it significantly reduces TTR protein levels, improving patients' quality of life.
In January 2024, Acino, a Switzerland-based pharmaceutical company, entered into a partnership with Sobi, a Sweden-based biopharmaceutical company, to enhance access to Tegsedi. This collaboration aims to expand the availability of essential therapies, including Tegsedi, to patients with rare diseases in Kazakhstan, improving treatment access in underserved areas. Through this partnership, both companies aim to provide more widespread access to life-changing therapies for those in need.
The key company operating in the tegsedi market is Ionis Pharmaceuticals Inc.
North America was the largest region in the tegsedi market in 2024. The regions covered in tegsedi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the tegsedi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tegsedi (inotersen) is a subcutaneous injection used to treat polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR), a condition where amyloid proteins build up in tissues, causing nerve damage. It works by inhibiting the production of transthyretin (TTR) protein, reducing amyloid deposits and alleviating neuropathic symptoms. Administered weekly via subcutaneous injection, it provides patients with a convenient self-administered treatment option.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for tegsedi include neurological manifestations, cardiac involvement, and other related conditions. Neurological manifestations refer to symptoms and signs caused by dysfunction of the nervous system, including the brain, spinal cord, and peripheral nerves. Tegsedi is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by a variety of end-users, such as hospitals, clinics, ambulatory care centers, and home care settings.
The tegsedi market consists of sales of subcutaneous injection, and prefilled syringe. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing demand for oral medications, increasing prevalence of comorbid conditions, rising awareness of rare genetic disorders, rising investment in precision medicine, and increasing number of clinical trials. Major trends in the forecast period include technological advancements, personalized medicine, genetic therapies, telemedicine, and combination therapies.
The growing adoption of personalized medicine is expected to significantly boost the growth of the tegsedi market in the future. Personalized medicine involves tailoring medical treatments based on an individual’s genetic profile, lifestyle, and environmental factors, resulting in more effective outcomes. The increased adoption of this approach is driven by advancements in genomic research, improved diagnostic tools, and a rising demand for more targeted therapies. Personalized medicine enhances the efficacy and safety of Tegsedi by customizing treatments for individuals with hereditary transthyretin-mediated amyloidosis, which ensures better therapeutic outcomes and minimizes risks. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, a significant increase from the six approved in 2022. As personalized medicine continues to expand, it will drive further growth in the tegsedi market.
A significant trend in the tegsedi market is the increasing adoption of innovative drug category pricing strategies. These strategies aim to improve accessibility, enhance patient adherence, and facilitate market penetration by balancing cost-effectiveness with therapeutic value. Drug category pricing involves setting prices for medications based on factors such as therapeutic category, efficacy, market demand, and competition within a specific drug class. In October 2021, PTC Therapeutics, a US-based biopharmaceutical company, announced that Tegsedi (inotersen) had received Category 1 classification from Brazil's Câmara de Regulação do Mercado de Medicamentos (CMED). This classification recognizes it as an innovative treatment that offers greater efficacy than existing therapies. Additionally, the Brazilian Health Regulatory Agency (Anvisa) approved it for treating Stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR). Tegsedi became the first antisense medication in Brazil to target the root cause of the disease, and clinical studies have shown that it significantly reduces TTR protein levels, improving patients' quality of life.
In January 2024, Acino, a Switzerland-based pharmaceutical company, entered into a partnership with Sobi, a Sweden-based biopharmaceutical company, to enhance access to Tegsedi. This collaboration aims to expand the availability of essential therapies, including Tegsedi, to patients with rare diseases in Kazakhstan, improving treatment access in underserved areas. Through this partnership, both companies aim to provide more widespread access to life-changing therapies for those in need.
The key company operating in the tegsedi market is Ionis Pharmaceuticals Inc.
North America was the largest region in the tegsedi market in 2024. The regions covered in tegsedi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the tegsedi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tegsedi (inotersen) is a subcutaneous injection used to treat polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR), a condition where amyloid proteins build up in tissues, causing nerve damage. It works by inhibiting the production of transthyretin (TTR) protein, reducing amyloid deposits and alleviating neuropathic symptoms. Administered weekly via subcutaneous injection, it provides patients with a convenient self-administered treatment option.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for tegsedi include neurological manifestations, cardiac involvement, and other related conditions. Neurological manifestations refer to symptoms and signs caused by dysfunction of the nervous system, including the brain, spinal cord, and peripheral nerves. Tegsedi is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by a variety of end-users, such as hospitals, clinics, ambulatory care centers, and home care settings.
The tegsedi market consists of sales of subcutaneous injection, and prefilled syringe. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Tegsedi Market Characteristics4. Tegsedi Market Trends And Strategies5. Tegsedi Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Tegsedi Pricing Analysis & Forecasts30. Global Tegsedi Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Tegsedi Market32. Recent Developments In The Tegsedi Market
3. Tegsedi Market Biologic Drug Characteristics
6. Global Tegsedi Growth Analysis And Strategic Analysis Framework
8. Tegsedi Market Segmentation
9. Global Tegsedi Epidemiology Of Clinical Indications
10. Tegsedi Market Regional And Country Analysis
11. Asia-Pacific Tegsedi Market
12. China Tegsedi Market
13. India Tegsedi Market
14. Japan Tegsedi Market
15. Australia Tegsedi Market
16. South Korea Tegsedi Market
17. Western Europe Tegsedi Market
18. UK Tegsedi Market
19. Germany Tegsedi Market
20. France Tegsedi Market
21. Eastern Europe Tegsedi Market
22. North America Tegsedi Market
23. USA Tegsedi Market
24. Canada Tegsedi Market
25. South America Tegsedi Market
26. Middle East Tegsedi Market
27. Africa Tegsedi Market
28. Tegsedi Market Competitive Landscape And Company Profiles
29. Global Tegsedi Market Pipeline Analysis
33. Tegsedi Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Tegsedi Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on tegsedi market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for tegsedi ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tegsedi market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Neurological Manifestations; Cardiac Involvement; Other Indications2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Profiled: Ionis Pharmaceuticals Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Ionis Pharmaceuticals Inc.
